Antiplatelet therapy for cardiovascular disease risk in patients with diabetes

Aspirin and other antiplatelet drugs are not routinely recommended for the primary prevention of cardiovascular disease; see Antiplatelet therapy and atherosclerotic cardiovascular disease risk for further discussion.

All adults with diabetes who have established atherosclerotic cardiovascular disease should receive an antiplatelet drug for the secondary prevention of cardiovascular events. See Antiplatelet drugs for detail of drug regimens.